Direct comparison
Blanket Consent vs. Broad Consent
Broad consent (45 CFR 46.116(d)) is a regulated IRB pathway with required disclosures; blanket consent is informal and unrestricted.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · free to try
Ask about Blanket Consent vs. Broad Consent
Ask your first 2 questions free below. Subscribers get 150 a day for $29 a month.
An AI assistant specialized in research administration. It cites the sources behind every answer, labels web answers and says when it can't answer.
Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.
Works on this site and inside Claude, Cursor and the AI tools you already use.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Blanket consent, Broad consent compare side by side?
The table below compares Blanket consent, Broad consent across 7 procurement-relevant dimensions, from regulatory status through compliance risk if conflated.
Side-by-side comparison
| Dimension | Blanket consent | Broad consent |
|---|---|---|
| Regulatory status | Not defined in the Common Rule, FDA regulations, or ICH E6 -- an informal, descriptive term. | Formally defined and regulated: 45 CFR 46.116(d), created by the 2018 revised Common Rule. |
| Scope of future use | Essentially unrestricted -- donation for any future research, as the term is generally used in the bioethics literature. | Bounded by a general description of research types the subject actually agreed to, even though specific future studies aren’t named. |
| Required disclosures | None specified -- content varies by institution, with no regulatory minimum. | Mandatory elements under 46.116(d): research-type description, information/biospecimen description, storage duration, non-notification statement, results-disclosure statement, contact information, plus standard 46.116(b) elements. |
| Ongoing oversight of secondary use | Not built in by definition -- may or may not include independent review, depending on institutional practice. | IRB review of each secondary study for fit within the agreed scope is the standard operating assumption. |
| Effect of refusal | No regulatory consequence defined -- depends entirely on institutional policy. | If refused, an IRB cannot later waive consent for that subject’s data/biospecimens under the 46.116(f) waiver pathway. |
| Typical use context | Loose shorthand in biobanking/bioethics discussion, sometimes used (imprecisely) as a synonym for broad consent. | The specific consent form/process an IRB reviews and approves for biobanks, repositories, and secondary-research programs. |
| Compliance risk if conflated | Labeling an actually-unrestricted process as "broad consent" overstates the protections built into it. | A form labeled "blanket consent" that skips 46.116(d)’s required elements may not legally qualify as broad consent at all. |
Common questions
Common questions about Blanket consent vs Broad consent
Is blanket consent legal under the Common Rule?
+
There is no Common Rule provision called "blanket consent." An IRB reviewing a consent process described that way needs to determine whether it actually meets 45 CFR 46.116(d)’s broad-consent requirements (if it’s meant to support a waiver of study-specific consent for secondary research) or whether it needs to be handled as a different, non-broad-consent informed-consent process.
Can broad consent and blanket consent be used interchangeably in an IRB protocol?
+
No. Using them interchangeably risks either understating what a truly unrestricted process requires, or overstating the protections in a process that hasn’t actually satisfied 46.116(d)’s specific disclosure elements. Protocols and consent forms should use "broad consent" only when the process genuinely meets that regulatory checklist.
What happens if a research subject refuses broad consent?
+
Under 45 CFR 46.116(e)-(f), if a subject was asked for broad consent and refused, an IRB cannot use the 46.116(f) waiver-of-consent pathway to bring that subject’s existing data or biospecimens into a secondary study anyway.
Does broad consent require IRB review of every secondary study?
+
The standard model is that the IRB reviews each proposed secondary use for fit within the scope the subject was told about at the time of broad consent -- broad consent is not a one-time approval for unlimited, unreviewed future use.
Going deeper
